Search

Your search keyword '"Aroldi, A"' showing total 54 results

Search Constraints

Start Over You searched for: Author "Aroldi, A" Remove constraint Author: "Aroldi, A" Publisher elsevier bv Remove constraint Publisher: elsevier bv
54 results on '"Aroldi, A"'

Search Results

1. Integrative multi-omics analysis enables a comprehensive characterization of prostate cancer and unveils metastasis-associated candidate biomarkers

2. Validation of a new NGS-based myeloid panel in acute myeloid leukemia: A single-center experience

3. Performance evaluation of the SIMBIO-SYS Stereo Imaging Channel on board BepiColombo/ESA spacecraft

4. 1093TiP An open-label, multicenter, phase I/II clinical trial of RP1 as a single agent and in combination with nivolumab in patients with solid tumors [IGNYTE]

7. 1093TiP An open-label, multicenter, phase I/II clinical trial of RP1 as a single agent and in combination with nivolumab in patients with solid tumors [IGNYTE]

8. 566TiP A first-in-human study of NUC-7738, a ProTide transformation of 3’-deoxyadenosine, in patients with advanced solid tumours (NuTide:701)

13. 549P Results of a first-in-human study of the ProTide thymidylate synthase inhibitor NUC-3373, in patients with advanced solid tumours (NuTide:301)

14. 464P Pharmacokinetic analysis of NUC-3373 with and without leucovorin in patients with previously treated metastatic colorectal cancer (NuTide:302 study)

16. Performance evaluation of the SIMBIO-SYS Stereo Imaging Channel on board BepiColombo/ESA spacecraft

17. Metformin Use Is Associated With Longer Progression-Free Survival of Patients With Diabetes and Pancreatic Neuroendocrine Tumors Receiving Everolimus and/or Somatostatin Analogues

20. Dignity Therapy: a new psychoterapeutic approach for people facing advanced disease

21. Hair loss prevention by scalp cooling device in early breast cancer patients: the Poliambulanza experience

22. Metformin impact on progression-free survival in diabetic patients with advanced pancreatic neuroendocrine tumors (pNET) receiving everolimus and/or somatostatin analogues. The PRIME-NET (Pancreatic multicentric, Retrospective, Italian MEtformin) study

23. Metformin impact on progression-free survival in diabetic patients with advanced pancreatic neuroendocrine tumors (pNET) receiving everolimus and/or somatostatin analogues. The PRIME-NET (Pancreatic multicentric, Retrospective, Italian MEtformin) study

24. Hypertension After Renal Transplantation

25. “Yoga project in Oncology: observational study of the Yoga effects in cancer patient. The Poliambulanza experience”

27. Chemotherapy rechallenge after regorafenib treatment in metastatic colorectal cancer. Still hope after the last hope?

28. 'Yoga project in Oncology: observational study of the Yoga effects in cancer patient. The Poliambulanza experience'

29. Long-term evolution of anti–HCV-positive renal transplant recipients

30. Who Should Receive First-Line Folfirinox? Prognostic Factors in Locally Advanced or Metastatic Pancreatic Cancer Patients

31. Single-Agent or Doublets As Second-Line Chemotherapy After Folfirinox in Patients with Locally Advanced or Metastatic Pancreatic Cancer

32. Single-Agent or Doublets As Second-Line Chemotherapy After Folfirinox in Patients with Locally Advanced or Metastatic Pancreatic Cancer

33. Design of a trial comparing sirolimus plus mycophenolate mofetil versus sirolimus plus cyclosporine

34. Long-term effects of single versus double CsA dosing in kidney transplantation

36. From cyclosporine to the future

39. Renal transplantation from older donors

50. Prevention of calcium nephrolithiasis with low-dose thiazide, amiloride and allopurinol

Catalog

Books, media, physical & digital resources